medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2012, Number 3

<< Back Next >>

Salud Mental 2012; 35 (3)

Los productos de Cannabis sativa: situación actual y perspectivas en medicina

Rodríguez CR

Language: Spanish
References: 98
Page: 247-256
PDF size: 337.95 Kb.


ABSTRACT

Psychoactive preparations of Cannabis sativa, such as marijuana and hashish, have been used for centuries for medicinal, religious and recreational purposes. Today marijuana is the most widely used illegal drug worldwide, particularly among teenagers and young adults. Adolescence is a critical phase in Central Nervous System development, characterized by neuronal maturation and rearrangement processes. Marijuana is very complex in its chemistry due to the large number of active constituents capable of interacting with each other. With inhaled marihuana, subjects experience euphoria, a feeling of relaxation, and intensification of ordinary sensory experiences. Chronic consumption results in tolerance, dependence, withdrawal syndrome, cognitive deterioration, and increased risk of psychiatric illnesses. The discovery of an endogenous cannabinoid system renewed the medical interest in marijuana and data from the last 20 years have shown that, in the postnatal brain, endocannabinoids regulate the function of many synapses and play an important role in brain development; also, that chronic consumption of marijuana early in life negatively affects Central Nervous System development. Recently, interest on marijuana has centered on its medicinal properties, and a good number of controlled clinical studies support its use in certain medical conditions; however, safety and efficacy of marijuana remains controversial. In this article we analyze the pharmacological knowledge on marijuana, the risks of its consumption, data on its medicinal properties and, based on the available evidence, we conclude that its legalization should be discouraged. Finally, we postulate that marijuana in its herbal form, by the enteral route, could be of a great value in mitigating suffering in patients with terminal illness.


REFERENCES

  1. Grotenhermen F. Pharmacokinetics and pharmacodinamycs of cannabinoids. Clin Pharmacokinet 2003;42:327-360.

  2. Elsohly MA, Slade D. Chemical constituients of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005;78:539-548.

  3. Hall W, Degenhardt L. Adverse health effects on non-medical cannabis use. Lancet 2009;374:1383-1391.

  4. Ashton CH. Pharmacology and effects of cannabis: a brief review. Brit J Psychiat 2001;178:101-106.

  5. Degenhardt L, Wall W. The association between psychosis and problematicl drug use among Australian adults: findings from the National Survey of Mental Health and Well Being. Psychol Med 2001;31:659-668.

  6. Merikangas KR, Metha RL, Molnar BE et al. Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Pyschiatric Epidemiology. Addict Behav 1998;23:893-907.

  7. UNODC. World drug report 2008. Viena: United Nations Office on Drugs and Crime; 2007.

  8. Degenhardt L, Chiu W, Sampson N, Kessler RC et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO world mental health surveys. Plos Med 2008;5:1053-1067.

  9. National Survey on Drug Use and Health (NSDUH) 2008. Disponible en http://nsduh.web.rti.org

  10. Monitoring the Future Survey (MFS) 2008. Disponible en hhtp://drugabuse.gov

  11. National Institute of Drug Abuse (NIDA). Disponible en http://drugabuse.gov

  12. Secretaría de Salud Encuesta Nacional de Adicciones 2008. Secretaría de Salud, México.

  13. Guxens M, Nebot M, Ariza C, Ochoa D. Factores asociados al inicio del consumo de cannabis: una revisión sistemática de estudios de cohortes. Gac Sanit 2007;19:1-9.

  14. Chao FC, Green DE, Forrest IS et al. The passage of 14C-delta-9-tetrahydrocannabinol into the milk of lactating squirrel monkeys. Res Commun Chem Pathol Pharmacol 1976;15:303-317.

  15. Harvey DJ, Brown NK. Comparative in vitro metabolism of the cannabinoids. Pharmacol Biochem Behav 1991;40:533-540.

  16. Agurrel S, Halldin M, Lindgren JE, Ohlsson A et al. Pharmacokinetics and metabolism of delta-1 tetrahydrocannbinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986;38:21-43.

  17. Schwartz RH, Hayden GF, Riddile M. Laboratory detection of marijuana use: experience with a photometric immunoassay to measure urinary cannabinoids. Am J Dis Child 1985;139:1093-1096.

  18. Parolaro D, Vigano D, Rubino T. Endocannabinoids and drug dependence. Curr Drug Tar 2005;4:643-655.

  19. Green B, Kavanagh D, Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 2003;22:453–460.

  20. Yesavage JA, Leirer VO, Denari M, Hollister LE. Carry-over effects of marijuana intoxication on aircraft pilot performance. A premilinary report. Am J Psychiatry 1985;142:1325-1329.

  21. Mccleod J, Oakes R, Copello A, Crome I et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 2004;363:1579-1588.

  22. Kalant H. Medicinal use of cannabis: history and current status. Pain Res Manag 2001;6:80-90.

  23. Reece AS. Cannabis and lung cancer. Eur Respir J 2008;31:280-6.

  24. Reece AS. Chronic toxicology of cannabis. Clin Toxicol 2009;47:517-524.

  25. Matsuda LA, Lolait SJ, Brownstein AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.

  26. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-180.

  27. Abood ME, Martin BR. Neurobiology of marijuana abuse. Trends Pharmacol Sci 1992;201-207.

  28. Alger BE, Kim J. Supply and demand for endocannabinoids. Trends Neurosci 2011;34:304-315.

  29. Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroinmunology 2005;166:3-18.

  30. Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949.

  31. De Petrocellis L, Melck D, Bisogno T, Di Marzo V. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids 2000;108:191-209.

  32. Maldonado R, Berrendero F, Ozaita A, Robledo P. Neurochemical basis of cannabis addiction. Neurosci 2011;181:1-17.

  33. Porter BC, Dey SK. The endocannabinoid nervous system. Unique opportunities for therapeutic intervention. Pharmacol Ther 2001;90:45-60.

  34. Van der Stelt M, Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic system: implications for neurological and psychiatric disorders. Eur J Pharmacol 2003;480:133-150.

  35. Harkany T, Guzman M, Galve-Roperth I, Berghuis P et al. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 2007;28:83-91.

  36. Berdyshev EV. Cannabinoid receptor and the regulation of the immune response. Chem Phys Lipids 2000;108:169-190.

  37. Kunos G, Jarai Z, Batkai S, Goparaju SK et al. Endocannabinoids as cardiovascular modulators. Chem Phys Lipids 2000;108:159-168.

  38. Randall MD, Harris D, Kendall DA, Ralevic V. Cardiovascular effects of cannabinoids. Pharmacol Ther 2002;95:191-202.

  39. Di Carlo G, Izzo AA. Cannabinoids for gastrointestinal diseases: potential therapeutic aplications. Expert Opin Invest Drugs 2003;12:39-49.

  40. Paria BC, Dey SK. Ligand-receptor signalling with endocannabinoids in preimplantation embryo development and implantation. Chem Phys Lipids 2000;108:211-220.

  41. Guzman M, Sanchez, C, Galve-Roperth I. Control of the cell survivial/death decisión by cannabinoids. J Mol Med 2001;78:613-625.

  42. Galve-Roperth I, Aguado T, Rueda D, Velasco G et al. Endocannabinoids: a new family of lipid mediators involved in the regulation of neural cell development. Curr Pharm Des 2006;12:2319-2325.

  43. Bernard C, Milh H, Morozov YM, Ben-Ari Y et al. Altering cannabinoid signaling during development disrupts neuronal activity. Proc Natl Acad Sci USA 2005;102:9388-393.

  44. Huizink AC, Mulder EJH. Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning of human offspring. Neurosci Behav Rev 2006;30:24-41.

  45. Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 13- o 16- year-olds prenatally exposed to cigaretts and marihuana. Neurotoxicol Teratol 2003;25:427-436.

  46. Richadson GA, Day NL, Goldschmidt L. Prenatal alcohol, marijuana, and tobacco use: infant mental and motor development. Neurotoxicol Teratol 1995;17:479-487.

  47. Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX et al. Brain delevopment during childhood and adolescence: a longitudinal MRI study. Nat Neurosci 1999;2:861-863.

  48. Spear LP. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 2000;24:417-463.

  49. Bartzokis G, Beckson M, Lu PH, Nuechterlein KH et al. Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imagin study. Arch Gen Psychatry 2001;58:461-465.

  50. Lichtman AH, Martin BR. Cannabinoid tolerance and dependence. Handb Exp Pharmacol 2005;168:691–717.

  51. Di Marzo V, De Petrocellis L. Plant, synthetic, and endogenous cannabinoids in medicine. Ann Rev Med 2006;57:553-574.

  52. Rubino T, Vigano D, Massi P, Spinello M et al. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 2000;39:1331-1336.

  53. Warner FA, Anthony JC. From the first drug use to drug dependence, developmental periods of risk for dependence upon marihuana, cocaine, and alcohol. Neuropharmacology 2002;26:479-488.

  54. Budney AJ, Novy PL, Hughes JR. Marihuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999;94:1311-1322.

  55. American Psychiatric Association. The Diagnostic and Statistical Manual onf Mental Disorders. Cuarta edición. (DSM-IV) and proposed draft revisions (DSM-5). 2000. Disponible en hhtp://www.psych.org

  56. Linford-Hughes A, Watson B, Kalk N, Reid A. Neuropharmacology of additction and it informs treatment. Brit Med Bull 2010;96:93-100.

  57. Muller-Vahl K, Emrich HM. Cannabinoids and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Exp Rev Neurother 2008;12:1037-1048.

  58. Friedman AS, Glassman K, Terras BA. Violent behavior as related to the use of marijuana and other drugs. J Addict Dis 2001;20:49-72.

  59. Patton GC, Coffey C, Carlin JB, Degenhardt L et al. Cannabis use and mental health in young people: cohort study. Brit Med J 2002;325:1195–1198.

  60. Zammit S, Allebeck P, Andreasson S, Lundberg I et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Bit Med J 2002;325:1199–203.

  61. Arseneault L, Cannon M, Poulton R, Murray R et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Brit Med J 2002;325:1212-1213.

  62. Andreasson S, Engstrom A, Allebeck P, Rydberg U. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet 1987;2:1483-1486.

  63. Caspi A, Moffitt TE, Cannon M, McClay J et al. Moderation of the effect of adolescents-onset cannabis use on adult psychosis by functional poly- morphism in the catechol-o-methyltransferase gene longitudinal evidence of a gene-enviroment interaction. Biol Psychiatry 2005;57:1117-1127.

  64. Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE et al. Cannaibis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-328.

  65. Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neursoci 2007;9:413-430.

  66. Petro DJ. Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 1980;21:81-85.

  67. Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW et al. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987;7:39-50.

  68. Noyes R, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9- tetrahydrocannabinol. J Clin Pharmacol 1975;15:139-143.

  69. Maurer M, Henn V, Dittrich A et al. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Neurol Sci 1990;240:1-4.

  70. Sieradzan KA, Fox SH, Hill M, Crossman AR et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study. Neurology 2001;57:2108-2111.

  71. Williams SJ, Hartley JP, Graham JD. Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax 1976;31:720-723.

  72. Hartley JP, Nogrady SG, Seaton A. Bronchodilator effect of delta1-tetrahydrocannabinol. Br J Clin Pharmacol 1978;5:523-525.

  73. Merritt JC, Olsen JL, Armstrong JR, McKinon SM. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas. J Pharm Pharmacol 1981;331:40-41.

  74. Jarvinen T, Pate DW, Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther 2002;95:203-220.

  75. Nuci C, Bari M, Spano A, Corasaniti M et al. 17Beta-estradiol prevents retinal ganglio cell loss induced by acute rise of intraocular pressure in rat. Prog Brain Res 2008;173:451-464.

  76. Durán M, Laporte JR, Capella D. Novedades sobre las potencialidades terapéuticas: cannabis y sistema cannabinoide. Med Clin 2004;122:390-398.

  77. Russo E. Future of Cannabis and Cannabinoids in Therapeutics. J Cannabis Therapeutics 2004;3:163-174.

  78. Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001;42:1266-1272.

  79. Glison I, Busalacchi M. Marijuana for intractable hiccups. Lancet 1998;351:267.

  80. Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotical evidence and the need for clinical research. J Psychoactive Drugs 1998;30:171-177.

  81. Mikuriya TH. Cannabis substitution: and adjunctive therapeutic tool in the treatment of alcoholism. Med Times 1970;98:187-191.

  82. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Inmunol 2005;5:400-411.

  83. Aggarwal SK, Carter Gt, Sullican MD, ZumBrunnen C et al. Medicinal use of cannabis in the United Sates: historical perspectives, current trends, and future directions. J Opioid Manag 2010;5:153-168.

  84. Ley General de Salud, México. www.salud.gob.mx/unidades/cdi/legis/lgs/index-indice.htm.

  85. MacCoun RJ. Drugs and the law: a psychological analysis of drug prohibition. Psychol Bull 1993;113:497–512.

  86. Joffe A, Yancy S. Legalization of marihuana: potential impact on youth. Am Acad Pediat 2004;113:632-638.

  87. Deglamorising cannabis [editorial]. Lancet 1995;346:1241.

  88. Kleber HD. Our current approach to drug abuse-progress, problems, proposals. N Engl J Med 1994;330:361-365.

  89. Monshouwer K, Vaan Laar M, Vollebergh WA. Buying cannabis in “coffee shops”. Drug Alcohol Rev 2011;30:148-156.

  90. Lane J, Gerstein D, Huang L, Wright D. Risk and protective factors for adolescent drug use: Findings from the 1997 national household survey on drug abuse. Disponible en: www.samhsa.gov/oas/NHSDA/NAC97/ Table_ of_Contents.htm. Accessed May 7, 2003.

  91. Census 2000 supplementary survey profile for United States. Disponible en: www.census.gov/ acs/ www/Products/Profiles/Single/2002/ACS/Tabular/010/01000US1.htm.

  92. Malone DT, Hill MN, Rubino T. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Brit J Pharmacol 2010;160:511-522.

  93. Hensen B. Cannabinoid therapeutics: high hopes for the future. Drug Discov Today 2005;10:459-462.

  94. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008;9:164.73.

  95. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Brit Med J 2004;329:253.

  96. Rodríguez R. Prescripción basada en la evidencia y la presencia de los productos milagro. En: Los retos de la salud en México. Coordinación de la Investigación Científica, UNAM. 2011 (en prensa).

  97. Robson P. Human studies of cannainoids and medicinal cannabis. Handb Exp Pharmacol 2005;168:719-756.

  98. Guindon J, Hohmann AG. The endocannabinoid system and cancer: therapeutic implication. Brit J Pharmacol 2011;163:1447-1463.




2020     |     www.medigraphic.com